Anika Therapeutics (ANIK) Net Margin (2010 - 2025)

Anika Therapeutics (ANIK) has 16 years of Net Margin data on file, last reported at 4.93% in Q4 2025.

• Net Margin for Q4 2025 came in at 4.93%, up 5840.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (up 3924.0% YoY), and the FY2025 annual result was 0.8%, up 3886.0% from the prior year.
• Net Margin fell to 4.93% in Q4 2025 per ANIK's latest filing, from 3.04% in the prior quarter.
• Over five years, Net Margin peaked at 17.12% in Q2 2021 and troughed at 589.86% in Q4 2023.
• A 5-year average of 52.41% and a median of 7.58% in 2022 frame the typical range for Net Margin.
• The sharpest annual moves came in 2023 and 2024: Net Margin sank 37170 bps in 2023, then jumped 52653 bps in 2024.
• A 5-year view of Net Margin shows it stood at 30.01% in 2021, then slumped by 627 bps to 218.16% in 2022, then tumbled by 170 bps to 589.86% in 2023, then soared by 89 bps to 63.33% in 2024, then surged by 92 bps to 4.93% in 2025.
• Business Quant data shows ANIK's Net Margin at 4.93% in Q4 2025, 3.04% in Q3 2025, and 2.4% in Q2 2025.